Neurocutaneous Syndromes — Written Clinical Reasoning · Phys Written Answers

Prompt

DCE-style written reasoning for Neurocutaneous Syndromes.

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Neurocutaneous Syndromes and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Zhang S, Yang G Neurofibromin in bone disease: Mechanisms and therapeutic implications (Review) Int J Mol Med, 2026.PMID 42464674
[2]Calonge Q, Hanin A, Dade M, Bailly L, et al. Epilepsy and disability in adults with tuberous sclerosis complex: a 16-year retrospective analysis J Neurol, 2026.PMID 42458074
[3]Zeppieri M, D'Esposito F, Gagliano C, Battista M, et al. Looking at Optic Nerve Sheath Meningiomas Through Genetics-From Clinic to Bench and Back Again Front Biosci (Schol Ed), 2026.PMID 42411653
[4]Erdem S, Amparore D, Re C, Verep S, et al. What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group World J Urol, 2026.PMID 42373875
[5]Pawlak KM, Jagielski M, Papanikolaou IS, Hong W, et al. Pancreatic cystic lesions in hereditary syndromes: Diagnostic role of endoscopic ultrasound Best Pract Res Clin Gastroenterol, 2026.PMID 42167859
[6]Miranda M, Ferreira C, Fernandes M, Lopes F, et al. Hereditary renal cell carcinoma surveillance protocols: a review of the literature and proposed recommendations Fam Cancer, 2026.PMID 41518461
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Neurocutaneous Syndromes and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Zhang S, Yang G Neurofibromin in bone disease: Mechanisms and therapeutic implications (Review) Int J Mol Med, 2026.PMID 42464674
[2]Calonge Q, Hanin A, Dade M, Bailly L, et al. Epilepsy and disability in adults with tuberous sclerosis complex: a 16-year retrospective analysis J Neurol, 2026.PMID 42458074
[3]Zeppieri M, D'Esposito F, Gagliano C, Battista M, et al. Looking at Optic Nerve Sheath Meningiomas Through Genetics-From Clinic to Bench and Back Again Front Biosci (Schol Ed), 2026.PMID 42411653
[4]Erdem S, Amparore D, Re C, Verep S, et al. What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group World J Urol, 2026.PMID 42373875
[5]Pawlak KM, Jagielski M, Papanikolaou IS, Hong W, et al. Pancreatic cystic lesions in hereditary syndromes: Diagnostic role of endoscopic ultrasound Best Pract Res Clin Gastroenterol, 2026.PMID 42167859
[6]Miranda M, Ferreira C, Fernandes M, Lopes F, et al. Hereditary renal cell carcinoma surveillance protocols: a review of the literature and proposed recommendations Fam Cancer, 2026.PMID 41518461
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922